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Prolonged Survival of Hearts Obtained From Chimeric Donors 
in a Mouse to Rat Xenotransplant Model 
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and T.E. Starzl 
UNTIL recently. it has been proposed that "indirect" 
recognition of xenogeneic antigens that were pro-
cessed and presented by self-antigen presenting cells (APC) 
played a major role in the initiation of CD4 + T-cell-
dependent xenograft rejection. I However, the observation 
that the tempo of xenograft rejection remains unaltered in 
MHC class II "knock out" recipients provides evidence for 
direct antigen presentation by donor APCs.2 The relative 
case with which organs obtained from chimeric donors 
reconstituted with bone marrow (BM) cells of recipient 
origin are accepted across allogeneic barriers provides 
further credence to the latter observation.3-" We have 
therefore attempted to study the survival of heterotopically 
transplanted hearts obtained from mice reconstituted with 
recipient-type (rat) BM in a mouse to rat concordant 
xenotransplant model. 
MATERIALS AND METHODS 
Animals. BIO.BR mice (H_2k) were used as BM recipients and 
heart donors: LEW rats (RTl') were used as BM donors and heart 
transplant recipients. 
Experimental Design. BIO.BR mice were lethally irradiated (9.S 
Gy) and reconstituted with 10K unfractionated LEW BM cells. At 
various times (48 and 130 days) after BM reconstitution, hearts 
from the chimeric mouse donors were heterotopically transplanted 
into LEW recipients. some of which also received tacrolimus (FK 
506: 1 mg/kg/d 1M) until rejection (Table 1). 
DetectIOn of Chimensm. The presence of cells of donor (LEW) 
origin in the lymphoid organs of mice reconstituted with rat BM 
was determined tw flow cytometry using biotinylated mouse anti-
LEW antibodies. Similar detectlon of rat and mouse cells in organs 
(heart and liver) obtained from chimeric mice was also attempted 
on cryosections usmg appropriate anti-MHC class II-specific anti-
bodies. 
Rat Antimouse Immune Responses. One-way MLR assays were 
performed using irradiated lymph node cells obtained from chi-
meric donors (BlO.BR mice) as stimulators and naive LEW lymph 
node cells as responders. Antibody responses in the cardiac xeno-
graft recipients were determined by a complement-dependent 
cytotoxicity assay. 
RESULTS AND DISCUSSION 
Of the mice reconstituted with xenogeneic BM. 20% died 
due to failure of engraftment. whereas an additional 15% 
suffered moderate to severe GVHD. Although these ani-
mals responded to FK 506 intervention. they were never-
theless not used as donors for subsequent heart transplan-
tation. Hearts obtained from either naive or BlO.BR donors 
reconstituted with syngeneic BM. when transplanted into 
untreated or FK 506-treated rats were rejected in <3 days 
(Table 1, groups L II. and III). Furthermore. the tempo of 
graft rejection was similar when hearts obtained from mice 
48 days postrat BM reconstitution, were transplanted into 
naive rat recipients (Table 1. group IV). A slight prolonga-
tion in heart survival was witnessed when organs trans-
planted into naive rat recipients were obtained from 
BlO.BR donors 130 days postxenogeneic (rat to mouse) BM 
transplantation (Table 1, group V). However. with the 
addition of FK 506. hearts obtained 130 days postreconsti-
tution from chimeric mice enjoyed a significantly prolonged 
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Table 1. Survival of Cardiac Xenografts Transplanted From Chimeric B10.BR Mice Into LEW Recipients 
Groups Organ Donor (B10.BR) n 
Normal 5 
Normal 5 
III 130 days postsyngeneic BMTx 10 
IV 48 days postxenogenelc BMTxt 5 
V 1 30 days postxenogeneic BMTx 5 
VI 130 days postxenogeneic BMTx 5 
., mglkgld 1M. 
'Rat to mouse BMTx. 
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Recipient (LEW) 
Treatment 
None 
FK 506" 
None or FK 506" 
None 
None 
FK 50S" 
Survival Days 
(X:!: SO) 
204 :!: 004 
2.6:!: 0.4 
3.0 
2.S:!: 0.4 
904 :!: 5.7 
20.7 :!: 8.5 
p 
.05 vs GIV 
.002 vs GV 
733 
734 
survival when transplanted into LEW recipients (P = .002; 
Table 1, group VI). It is of interest to note that the 
appearance of antimouse cytotoxic antibodies in the serum 
of FK 506-treated (group VI) animals was significantly 
delayed. Additionally, in vitro MLR assays performed using 
irradiated lymphocytes from chimeric BlO.BR mice re-
vealed their inability to stimulate naive LEW lymphocytes. 
When tested for chimerism at 48 and 130 days postre-
constitution, 50% to 90% of cells in the lymphoid organs of 
mice were that of donor (rat) origin. A similar level of 
chimerism was also witnessed in immunostained cryosec-
tions of nonlymphoid (heart and liver) organs obtained 
from chimeric mice at 130 days postreconstitution. In 
conclusion, these experiments suggest that resident "pas-
senger" leukocytes may play an important role in xenoan-
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tigen recognition, tempting us to speculate that the gener-
ation of a hematopoietic chimeric donor may be added to 
the therapeutic armamentarium currently employed to 
overcome concordant xenograft rejection. 
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